Andrew Callos M.'s most recent trade in Cytokinetics Inc was a trade of 15,000 Common Stock done at an average price of $23.3 . Disclosure was reported to the exchange on Jan. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share. | 05 Jan 2026 | 15,000 | 65,440 (0%) | 0% | 23.3 | 348,900 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 60.28 per share. | 05 Jan 2026 | 15,000 | 50,440 (0%) | 0% | 60.3 | 904,200 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 15,000 | 99,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew Callos M. | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 62.09 per share. | 02 Jan 2026 | 913 | 50,440 (0%) | 0% | 62.1 | 56,688 | Common Stock |
| Cytokinetics Inc | Andrew Callos M. | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 885 | 1,772 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew Callos M. | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.63 per share. | 02 Jan 2026 | 885 | 51,325 (0%) | 0% | 37.6 | 33,303 | Common Stock |
| Cytokinetics Inc | Callos M. Andrew | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 63.16 per share. | 02 Jan 2026 | 885 | 50,440 (0%) | 0% | 63.2 | 55,897 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 62.44 per share. | 29 Dec 2025 | 1,809 | 51,353 (0%) | 0% | 62.4 | 112,954 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 1,589 | 52,249 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 1,588 | 53,837 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.72 per share. | 22 Dec 2025 | 675 | 53,162 (0%) | 0% | 62.7 | 42,336 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.13 per share. | 08 Dec 2025 | 1,042 | 51,702 (0%) | 0% | 39.1 | 40,773 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 1,042 | 35,403 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.96 per share. | 08 Dec 2025 | 1,042 | 50,660 (0%) | 0% | 66.0 | 68,730 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.95 per share. | 05 Dec 2025 | 52,486 | 50,660 (0%) | 0% | 66.0 | 3,461,452 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 15,858 | 15,857 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.63 per share. | 05 Dec 2025 | 15,858 | 92,518 (0%) | 0% | 37.6 | 596,737 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share. | 05 Dec 2025 | 15,000 | 65,660 (0%) | 0% | 23.3 | 348,900 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 15,000 | 114,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 11,000 | 36,445 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.13 per share. | 05 Dec 2025 | 11,000 | 76,660 (0%) | 0% | 39.1 | 430,430 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 10,628 | 2,657 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.63 per share. | 05 Dec 2025 | 10,628 | 103,146 (0%) | 0% | 37.6 | 399,932 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.02 per share. | 03 Dec 2025 | 1,368 | 50,660 (0%) | 0% | 65.0 | 88,947 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.04 per share. | 05 Jun 2025 | 8,659 | 52,028 (0%) | 0% | 32.0 | 277,434 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 05 May 2025 | 4,002 | 60,687 (0%) | 0% | 36.7 | 146,793 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.78 per share. | 07 Apr 2025 | 2,886 | 64,689 (0%) | 0% | 35.8 | 103,261 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share. | 17 Mar 2025 | 20,900 | 58,563 (0%) | 0% | 23.3 | 486,134 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 20,900 | 129,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.14 per share. | 17 Mar 2025 | 20,900 | 37,663 (0%) | 0% | 45.1 | 943,426 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.38 per share. | 17 Mar 2025 | 2,775 | 34,888 (0%) | 0% | 44.4 | 123,155 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 47,593 | 47,593 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 32,687 | 70,350 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 2,749 | 2,749 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 100 | 149,900 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 14 Mar 2025 | 100 | 37,663 (0%) | 0% | 45 | 4,500 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share. | 14 Mar 2025 | 100 | 37,763 (0%) | 0% | 23.3 | 2,326 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 43.62 per share. | 13 Mar 2025 | 26,771 | 37,663 (0%) | 0% | 43.6 | 1,167,751 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 43.27 per share. | 06 Mar 2025 | 3,341 | 64,434 (0%) | 0% | 43.3 | 144,565 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 42.88 per share. | 03 Mar 2025 | 1,114 | 67,775 (0%) | 0% | 42.9 | 47,768 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 3,177 | 68,889 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 3,176 | 67,063 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.51 per share. | 03 Dec 2024 | 1,351 | 65,712 (0%) | 0% | 51.5 | 69,590 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 18,346 | 18,346 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 16,941 | 63,887 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 1,224 | 1,224 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.88 per share. | 04 Mar 2024 | 5,103 | 46,946 (0%) | 0% | 66.9 | 341,289 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.68 per share. | 04 Mar 2024 | 2,202 | 52,049 (0%) | 0% | 67.7 | 149,031 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 47,445 | 47,445 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 30,000 | 53,683 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 2,555 | 2,555 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.60 per share. | 02 Mar 2023 | 2,202 | 23,683 (0%) | 0% | 39.6 | 87,199 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.13 per share. | 16 Feb 2023 | 969 | 25,885 (0%) | 0% | 44.1 | 42,762 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 31,715 | 31,715 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 20,000 | 26,196 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 13,285 | 13,285 | - | - | Incentive Stock Option (right to buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 3,125 | 6,196 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 1,919 | 3,071 (0%) | 0% | 0 | Common Stock |